Cite
HARVARD Citation
Resteghini, C. et al. (2017). Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best practice & research. 31 (3), pp. 349-361. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Resteghini, C. et al. (2017). Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best practice & research. 31 (3), pp. 349-361. [Online].